Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE40.4500
- TODAY'S CHANGE (%)-0.1300 (-0.3204%)
- Bid / Lots35.0000/ 1
- Ask / Lots64.6500/ 2
- Open / Previous Close41.0800 / 40.5800
- Day Range
- 52 Week Range
- Volume355,417
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 1394 | 40.925 |
| 09:34 ET | 600 | 41.265 |
| 09:36 ET | 200 | 41.5 |
| 09:38 ET | 2100 | 41.5 |
| 09:39 ET | 300 | 41.55 |
| 09:41 ET | 200 | 41.5 |
| 09:43 ET | 300 | 41.55 |
| 09:45 ET | 200 | 41.5 |
| 09:48 ET | 136 | 41.41 |
| 09:50 ET | 700 | 41.52 |
| 09:52 ET | 300 | 41.42 |
| 09:54 ET | 300 | 41.5 |
| 09:56 ET | 100 | 41.5 |
| 09:57 ET | 200 | 41.5 |
| 10:01 ET | 100 | 41.47 |
| 10:03 ET | 100 | 41.33 |
| 10:08 ET | 100 | 41.335 |
| 10:14 ET | 200 | 41.47 |
| 10:17 ET | 100 | 41.24 |
| 10:28 ET | 200 | 41.44 |
| 10:30 ET | 652 | 41.34 |
| 10:33 ET | 100 | 41.34 |
| 10:37 ET | 564 | 41.24 |
| 10:39 ET | 300 | 41.05 |
| 10:42 ET | 100 | 41.1 |
| 10:44 ET | 200 | 41.06 |
| 10:50 ET | 400 | 41.15 |
| 10:51 ET | 100 | 41.27 |
| 10:53 ET | 1100 | 41.305 |
| 10:55 ET | 400 | 41.44 |
| 10:57 ET | 1700 | 41.44 |
| 11:00 ET | 100 | 41.38 |
| 11:02 ET | 100 | 41.34 |
| 11:09 ET | 700 | 41.5 |
| 11:11 ET | 300 | 41.46 |
| 11:13 ET | 100 | 41.49 |
| 11:15 ET | 100 | 41.515 |
| 11:18 ET | 200 | 41.47 |
| 11:20 ET | 1000 | 41.4 |
| 11:22 ET | 100 | 41.4 |
| 11:29 ET | 601 | 41.6 |
| 11:31 ET | 600 | 41.64 |
| 11:36 ET | 317 | 41.82 |
| 11:38 ET | 1145 | 41.78 |
| 11:40 ET | 100 | 41.745 |
| 11:44 ET | 249 | 41.77 |
| 11:45 ET | 800 | 41.73 |
| 11:49 ET | 130 | 41.72 |
| 11:51 ET | 105 | 41.725 |
| 11:56 ET | 5621 | 41.66 |
| 11:58 ET | 200 | 41.655 |
| 12:00 ET | 3503 | 41.57 |
| 12:02 ET | 1201 | 41.53 |
| 12:03 ET | 2802 | 41.53 |
| 12:05 ET | 12089 | 41.64 |
| 12:12 ET | 100 | 41.63 |
| 12:16 ET | 200 | 41.675 |
| 12:20 ET | 2572 | 41.55 |
| 12:21 ET | 323 | 41.55 |
| 12:23 ET | 250 | 41.53 |
| 12:25 ET | 1815 | 41.45 |
| 12:27 ET | 100 | 41.41 |
| 12:36 ET | 300 | 41.405 |
| 12:39 ET | 500 | 41.44 |
| 12:41 ET | 825 | 41.38 |
| 12:43 ET | 100 | 41.38 |
| 12:45 ET | 200 | 41.465 |
| 12:48 ET | 8544 | 41.36 |
| 12:50 ET | 100 | 41.42 |
| 12:52 ET | 1696 | 41.37 |
| 12:54 ET | 100 | 41.31 |
| 12:56 ET | 400 | 41.34 |
| 12:57 ET | 900 | 41.285 |
| 12:59 ET | 800 | 41.255 |
| 01:01 ET | 529 | 41.26 |
| 01:03 ET | 1900 | 41.21 |
| 01:06 ET | 100 | 41.21 |
| 01:10 ET | 700 | 41.18 |
| 01:12 ET | 600 | 41.12 |
| 01:14 ET | 2004 | 41.125 |
| 01:15 ET | 1500 | 41.135 |
| 01:19 ET | 2000 | 41.185 |
| 01:21 ET | 100 | 41.2 |
| 01:26 ET | 900 | 41.2 |
| 01:28 ET | 300 | 41.18 |
| 01:32 ET | 300 | 41.125 |
| 01:33 ET | 100 | 41.125 |
| 01:37 ET | 200 | 41.125 |
| 01:39 ET | 100 | 41.125 |
| 01:42 ET | 700 | 41.1 |
| 01:44 ET | 700 | 41.12 |
| 01:46 ET | 528 | 41.05 |
| 01:50 ET | 600 | 41.045 |
| 01:53 ET | 900 | 41 |
| 01:55 ET | 498 | 40.94 |
| 01:57 ET | 7168 | 40.75 |
| 02:00 ET | 1100 | 40.77 |
| 02:02 ET | 400 | 40.68 |
| 02:04 ET | 811 | 40.66 |
| 02:06 ET | 962 | 40.66 |
| 02:08 ET | 400 | 40.63 |
| 02:09 ET | 600 | 40.675 |
| 02:11 ET | 1000 | 40.71 |
| 02:15 ET | 800 | 40.68 |
| 02:18 ET | 1522 | 40.67 |
| 02:20 ET | 600 | 40.68 |
| 02:22 ET | 568 | 40.69 |
| 02:24 ET | 800 | 40.75 |
| 02:26 ET | 300 | 40.795 |
| 02:27 ET | 200 | 40.77 |
| 02:29 ET | 200 | 40.78 |
| 02:31 ET | 200 | 40.755 |
| 02:33 ET | 1300 | 40.82 |
| 02:38 ET | 300 | 40.905 |
| 02:40 ET | 200 | 40.8975 |
| 02:42 ET | 100 | 40.905 |
| 02:44 ET | 800 | 40.94 |
| 02:45 ET | 200 | 40.925 |
| 02:47 ET | 700 | 40.89 |
| 02:49 ET | 4502 | 40.74 |
| 02:51 ET | 476 | 40.79 |
| 02:54 ET | 2000 | 40.74 |
| 02:56 ET | 500 | 40.805 |
| 02:58 ET | 118 | 40.815 |
| 03:00 ET | 300 | 40.81 |
| 03:02 ET | 300 | 40.72 |
| 03:03 ET | 2363 | 40.73 |
| 03:05 ET | 900 | 40.75 |
| 03:07 ET | 999 | 40.7 |
| 03:09 ET | 2300 | 40.72 |
| 03:12 ET | 1300 | 40.61 |
| 03:14 ET | 100 | 40.59 |
| 03:18 ET | 1100 | 40.555 |
| 03:20 ET | 200 | 40.51 |
| 03:21 ET | 500 | 40.505 |
| 03:23 ET | 200 | 40.46 |
| 03:25 ET | 200 | 40.46 |
| 03:27 ET | 1300 | 40.45 |
| 03:30 ET | 236 | 40.34 |
| 03:32 ET | 314 | 40.35 |
| 03:34 ET | 5933 | 40.41 |
| 03:36 ET | 1592 | 40.43 |
| 03:38 ET | 1608 | 40.471 |
| 03:39 ET | 1775 | 40.41 |
| 03:41 ET | 2313 | 40.42 |
| 03:43 ET | 500 | 40.455 |
| 03:45 ET | 6572 | 40.46 |
| 03:48 ET | 2169 | 40.4 |
| 03:50 ET | 1294 | 40.315 |
| 03:52 ET | 6154 | 40.32 |
| 03:54 ET | 3036 | 40.15 |
| 03:56 ET | 18088 | 40.33 |
| 03:57 ET | 9145 | 40.39 |
| 03:59 ET | 11448 | 40.45 |
May 10, 2024
DJ Xenon Pharmaceuticals Is Maintained at Buy by Needham, from 6:12PM ET on Friday May 10, 2024 by Dow Jones
6:12PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Buy by Citigroup, from 5:48PM ET on Friday May 10, 2024 by Dow Jones
5:48PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush, from 9:30AM ET on Friday May 10, 2024 by Dow Jones
9:30AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones*DJ Xenon Pharmaceuticals 1Q Loss/Shr 62c >XENE, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 3.1B | -14.9x | --- |
Apogee Therapeutics Inc | 3.0B | -30.7x | --- |
Iovance Biotherapeutics Inc | 3.0B | -5.9x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
SpringWorks Therapeutics Inc | 3.2B | -8.8x | --- |
Biohaven Ltd | 3.3B | -5.4x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -14.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
